________________________________________________________________________________



                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549


                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): November 16, 2004


                         PROVECTUS PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


          Nevada                    000-9410                      90-0031917
(State or other jurisdiction       (Commission                  (IRS Employer
     of incorporation)             File Number)              Identification No.)



              7327 Oak Ridge Highway, Suite A
                    Knoxville, Tennessee                           37931
          (Address of principal executive offices)               (Zip Code)



       Registrant's telephone number, including area code: (865) 769-4011


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

________________________________________________________________________________

<PAGE>

Item 3.02.  Unregistered Sales of Equity Securities.

On  November  16,  2004,  Provectus  Pharmaceuticals,  Inc.  completed a private
placement  transaction with 14 accredited  investors,  pursuant to which we sold
556,832 shares of our common stock at a purchase  price of $0.75 per share,  for
an aggregate  purchase  price of  $417,624.25  pursuant to  Securities  Purchase
Agreements with each investor.  In connection with the sale of the common stock,
we also issued  warrants  (the  "Warrants")  to the  investors to purchase up to
835,249 shares of our common stock at an exercise  price of $1.00 per share.  We
paid $41,762.43 to Venture  Catalyst,  LLC, 170 East 77th Street,  Apt. 10F, New
York, NY 10021 as placement agent for this  transaction.  The form of Securities
Purchase Agreement entered into by each of the investors and the form of Warrant
issued to the investors is attached hereto as Exhibit 4.1 and 4.2.

We believe that this offering was exempt from the  registration  requirements of
the Securities Act of 1933, as amended (the "Securities  Act") by reason of Rule
506 of Regulation D and Section 4(2) of the Securities  Act, based upon the fact
that the offer and issuance of the common stock and warrants  satisfied  all the
terms and conditions of Rules 501 and 502 of the  Securities  Act, the investors
are financially  sophisticated and had access to complete information concerning
us and  acquired  the  securities  for  investment  and  not  with a view to the
distribution thereof. Proceeds will be used for general corporate purposes.

Item 9.01. Exhibits.

(c)      Exhibits.

     Exhibit
     Number                           Description
-----------------    -----------------------------------------------------------
      4.1            Form of Securities Purchase Agreement
      4.2            Form of Warrant



<PAGE>

                                    SIGNATURE


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  November 19, 2004

                                            PROVECTUS PHARMACEUTICALS, INC.

                                            By:  /s/ Timothy C. Scott
                                               -------------------------------
                                               Timothy C. Scott, Ph.D.
                                               President




<PAGE>


                                  EXHIBIT INDEX


 Exhibit
 Number                                    Description
-----------------    -----------------------------------------------------------

      4.1            Form of Securities Purchase Agreement

      4.2            Form of Warrant
[{"type": "8-K", "sequence": "1", "filename": "provectus8k111804.txt", "description": "CURRENT REPORT", "secsgml_size_bytes": 4633}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "041157932"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
________________________________________________________________________________

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

       Date of Report (Date of earliest event reported): November 16, 2004

                         PROVECTUS PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)

          Nevada                    000-9410                      90-0031917
(State or other jurisdiction       (Commission                  (IRS Employer
     of incorporation)             File Number)              Identification No.)

              7327 Oak Ridge Highway, Suite A
                    Knoxville, Tennessee                           37931
          (Address of principal executive offices)               (Zip Code)

       Registrant's telephone number, including area code: (865) 769-4011

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ]  Written communications pursuant to Rule 425 under the Securities Act
     (17 CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
     (17 CFR 240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.13e-4(c))

________________________________________________________________________________
Item 3.02.  Unregistered Sales of Equity Securities.

On  November  16,  2004,  Provectus  Pharmaceuticals,  Inc.  completed a private
placement  transaction with 14 accredited  investors,  pursuant to which we sold
556,832 shares of our common stock at a purchase  price of $0.75 per share,  for
an aggregate  purchase  price of  $417,624.25  pursuant to  Securities  Purchase
Agreements with each investor.  In connection with the sale of the common stock,
we also issued  warrants  (the  "Warrants")  to the  investors to purchase up to
835,249 shares of our common stock at an exercise  price of $1.00 per share.  We
paid $41,762.43 to Venture  Catalyst,  LLC, 170 East 77th Street,  Apt. 10F, New
York, NY 10021 as placement agent for this  transaction.  The form of Securities
Purchase Agreement entered into by each of the investors and the form of Warrant
issued to the investors is attached hereto as Exhibit 4.1 and 4.2.

We believe that this offering was exempt from the  registration  requirements of
the Securities Act of 1933, as amended (the "Securities  Act") by reason of Rule
506 of Regulation D and Section 4(2) of the Securities  Act, based upon the fact
that the offer and issuance of the common stock and warrants  satisfied  all the
terms and conditions of Rules 501 and 502 of the  Securities  Act, the investors
are financially  sophisticated and had access to complete information concerning
us and  acquired  the  securities  for  investment  and  not  with a view to the
distribution thereof. Proceeds will be used for general corporate purposes.

Item 9.01. Exhibits.

(c)      Exhibits.

     Exhibit
     Number                           Description
-----------------    -----------------------------------------------------------
      4.1            Form of Securities Purchase Agreement
      4.2            Form of Warrant
SIGNATURE

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  November 19, 2004

                                            PROVECTUS PHARMACEUTICALS, INC.

                                            By:  /s/ Timothy C. Scott
                                               -------------------------------
                                               Timothy C. Scott, Ph.D.
                                               President
EXHIBIT INDEX

 Exhibit
 Number                                    Description
-----------------    -----------------------------------------------------------

      4.1            Form of Securities Purchase Agreement

      4.2            Form of Warrant